Filing Details

Accession Number:
0001104659-24-085835
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-08-05 16:30:18
Reporting Period:
2024-08-01
Accepted Time:
2024-08-05 16:30:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1750284 Olema Pharmaceuticals Inc. OLMA Pharmaceutical Preparations (2834) 300409740
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1854392 Ltd. Fund International Biocapital Paradigm 767 Third Avenue, 17Th Floor
New York NY 10017
No No Yes No
1855655 Paradigm Biocapital Advisors Lp 767 Third Avenue, 17Th Floor
New York NY 10017
No No Yes No
1994082 Paradigm Biocapital Advisors Gp Llc 767 Third Avenue, 17Th Floor
New York NY 10017
No No Yes No
1994183 Senai Asefaw 767 Third Avenue, 17Th Floor
New York NY 10017
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.0001 Per Share Disposition 2024-08-01 1,870,499 $14.92 4,720,482 No 4 S Indirect By: Paradigm BioCapital International Fund Ltd.
Common Stock, Par Value $0.0001 Per Share Disposition 2024-08-01 529,501 $14.92 783,118 No 4 S Indirect By: One or more separately managed accounts
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By: Paradigm BioCapital International Fund Ltd.
No 4 S Indirect By: One or more separately managed accounts
Footnotes
  1. These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.
  2. These securities are held directly by one or more separately managed accounts managed by the Adviser. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.